In a significant advancement, Biocon Biologics has gained marketing approval for its pegfilgrastim biosimilar in Japan. This vital cancer supportive care drug is designed to mitigate infection risks following chemotherapy. Developed as a rival to Neulasta, Sandoz KK will handle its exclusive promotion and distribution. This approval marks a pivotal step in expanding Biocon's biosimilar range and improving patient accessibility worldwide.